Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bone Repair Cells

Cell therapy · Cell replacement · developed by Vericel

Phase 1/2 Most advanced trial (none active)
VCEL Developer
1 Registered trials

What is Bone Repair Cells?

Bone Repair Cells are autologous bone marrow cells administered during spine fusion surgery. They are studied in single-level posterolateral spinal fusion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Cell replacement
Therapy area
Musculoskeletal
Developer
Vericel Corporation (VCEL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00797550 Phase 1/2 Single Level Posterolateral Spinal Fusion Terminated VCEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Single Level Posterolateral Spinal Fusion

More from Vericel

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VCEL page.

Follow VCEL, the company behind Bone Repair Cells

See VCEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VCEL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.